Stimulants: Therapeutic Actions in ADHD
The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
Stimulants such as methylphenidate and amphetamine are currently the most common treatment for attention deficit hyperactivity disorder (ADHD). For years, it was assumed that stimulants had paradoxical calming effects in ADHD patients, whereas stimulating 'normal' individuals and producing locomotor activation in rats. It is now known that low doses of stimulants focus attention and improve executive function in both normal and ADHD subjects. Furthermore, the seminal work of Kuczenski and Segal showed that low, oral doses of methylphenidate reduce locomotor activity in rats as well. Berridge et al have now shown that these low doses produce marked increases in norepinephrine and dopamine release in the prefrontal cortex, whereas having only subtle effects on subcortical catecholamine release. ihe prefrontal cortex regulates behavior and attention using representational knowledge, and imaging and neuropsychological studies have shown that the prefrontal cortex is weaker in subjects with ADHD. This cortical area is very sensitive to levels of catecholamines: moderate levels engage postsynaptic alpha2A-adrenoceptors and D1 receptors and improve prefrontal regulation of behavior and attention, while high levels impair prefrontal function via alpha1-adrenoceptors and excessive D1 receptor stimulation. Administering low doses of methylphenidate to rats improves the working memory and attentional functions of the prefrontal cortex, while high doses impair working memory and produce…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stimulants, such as those used to treat attention-deficit/hyperactivity disorder (ADHD), preferentially modulate central DA and, to a lesser extent, NE systems (Arnsten, 2006).”
From Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder (2014) · cites this paper as Arnsten, 2006
In the citing paper
“For college students with ADHD who have difficulties with attention and neuropsychological deficits (NPDs; e.g., difficulties with EFs) due to dopamine deficits, stimulant medication helps these students by increasing dopamine to typical levels (Arnsten, 2006; Dela Peña et al., 2015; Willcutt, 2015).”
From Effects of stimulant medication on neuropsychological functioning in college students without ADHD. (2026) · cites this paper as Arnsten, 2006
In the citing paper
“stimulants like methylphenidate and amphetamine, which increase prefrontal catecholamines, have commonly been used to treat cognitive dysfunction such as working memory impairments in patients with ADHD (Arnsten 2006, Pietrzak et al 2006).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Arnsten 2006, Pietrzak et al 2006
Citations
Cites
Inhibition and the right inferior frontal cortex
Aron, A. R., Robbins, T. W., & Poldrack, R. A. (2004) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2004.02.010 · Cited by 3,197 · cited 2×
“The right inferior prefrontal cortex is particularly important for behavioral inhibition (reviewed in Aron et al, 2004).”
BackgroundCellular basis of working memory
Goldman-Rakic, P. S. (1995) · Neuron · doi:10.1016/0896-6273(95)90304-6 · Cited by 2,663 · cited 2×
“Moderate levels of D1/D5 receptor stimulation suppress delay-related firing for nonpreferred spatial directions (ie ‘noise’), and thus enhance spatial tuning (Williams and Goldman-Rakic, 1995; Vijayraghavan et al, 2006).”
BackgroundMolecular genetics of attention-deficit/hyperactivity disorder
Faraone, S. V., Perlis, R. H., Doyle, A. E., Smoller, J. W., Goralnick, J. J., Holmgren, M. A., & Sklar, P. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.024 · Cited by 2,357 · cited 2×
“ADHD is often an inherited disorder, and many of the genes associated with ADHD code for molecules involved with catecholamine transmission (reviewed in Faraone et al, 2005).”
BackgroundVan Tol, H. H. M., Bunzow, J. R., Guan, H.-C., Sunahara, R. K., Seeman, P., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,014 · cited 1×
“It should be noted that the D4 receptor has very high affinity for norepinephrine (Van Tol et al, 1991) and should really be considered a catecholamine receptor.”
BackgroundPrinciples of Frontal Lobe Function
(2002) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195134971.001.0001 · Cited by 1,665
Castellanos, F. X. (2002) · JAMA · doi:10.1001/jama.288.14.1740 · Cited by 1,646 · cited 2×
“Many of these studies have also found reduced volume of cerebellum, caudate, and corpus callosum (Seidman et al, 2005; Castellanos et al, 2002).”
BackgroundModulation of memory fields by dopamine Dl receptors in prefrontal cortex
Williams, G. V., & Goldman-Rakic, P. S. (1995) · Nature · doi:10.1038/376572a0 · Cited by 1,593 · cited 1×
“Moderate levels of D1/D5 receptor stimulation suppress delay-related firing for nonpreferred spatial directions (ie ‘noise’), and thus enhance spatial tuning (Williams and Goldman-Rakic, 1995; Vijayraghavan et al, 2006).”
BackgroundImpairment of social and moral behavior related to early damage in human prefrontal cortex
Anderson, S. W., Bechara, A., Damasio, H., Tranel, D., & Damasio, A. R. (1999) · Nature Neuroscience · doi:10.1038/14833 · Cited by 1,539 · cited 1×
“Lesions in the ventromedial prefrontal cortex can impair regulation of emotion, and result in inappropriate social behaviors such as aggression (Anderson et al, 1999).”
BackgroundDissociation in prefrontal cortex of affective and attentional shifts
Dias, R., Robbins, T. W., & Roberts, A. C. (1996) · Nature · doi:10.1038/380069a0 · Cited by 1,527 · cited 1×
“Similar results have been seen in animals, where prefrontal cortex lesions impair attentional regulation in monkeys (Malmo, 1942; Bartus and Levere, 1977; Dias et al, 1996), and rats (Muir et al, 1996).”
ResultADHD and The Nature of Self-Control
Barkley, R. A., & Wasserstein, J. (2000) · Journal of Cognitive Psychotherapy · doi:10.1891/0889-8391.14.1.111 · Cited by 1,513
Cited by
Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system
Lammel, S., Hetzel, A., Häckel, O., Jones, I., Liss, B., & Roeper, J. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.022 · Cited by 976
“The dopamine midbrain system is not only involved in motor control and movement disorders like Parkinson disease, but also plays a crucial part in many emotional and cognitive functions of the brain and its major disturbances in schizophrenia, drug addiction, and attention deficit hyperactivity disorder (ADHD) (Bjorkl…”
Swanson, J. M., Kinsbourne, M., Nigg, J., Lanphear, B., Stefanatos, G. A., Volkow, N., Taylor, E., Casey, B. J., Castellanos, F. X., & Wadhwa, P. D. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9019-9 · Cited by 580
“and 16p; Bakker et al.: 15q, 7p, and 9q). Thus, the directions for the next step in the search for genes associated with ADHD were not consistent across these two genome scans. The failure to detect a strong signal does not discount the existence of genes with high-probability risk alleles, multiple genes that combine…”
BackgroundEagle, D. M., Bari, A., & Robbins, T. W. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1127-6 · Cited by 548
“( Arnsten 2006; Arnsten and Li 2005; Cardinal 2006 ;C ardinal et al.2004; Chamberlain and Sahakian 2007; Dalley et al. 2004; Davids et al. 2003; Evenden and Ryan 1996; Robbins 2002; Robbins and Everitt 1987; Winstanley et al. 2006).”
BackgroundPaying attention to reading: The neurobiology of reading and dyslexia
Shaywitz, S. E., & Shaywitz, B. A. (2008) · Development and Psychopathology · doi:10.1017/s0954579408000631 · Cited by 545
“…in the brain and that newer agents such as “. . . atomoxetine (Strattera) also increases norepinephrine and dopamine release in the prefrontal cortex . . . ,” suggesting “that catecholamine release in the prefrontal cortex may be a common action for many ADHD therapeutics” (Arnsten, 2006b, p. 2).”
BackgroundInfluentialTripp, G., & Wickens, J. R. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.026 · Cited by 492
“Some theories argue for an involvement of norepinephrine (Arnsten, 2006; Pliszka et al., 1996) or serotonin (Gainetdinov et al.”
BackgroundRubia, K., Halari, R., Cubillo, A., Mohammad, A.-M., Brammer, M., & Taylor, E. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.013 · Cited by 393
The neuromodulator of exploration: A unifying theory of the role of dopamine in personality
DeYoung, C. G. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00762 · Cited by 387
Robinson, E. S. J., Eagle, D. M., Mar, A. C., Bari, A., Banerjee, G., Jiang, X., Dalley, J. W., & Robbins, T. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301487 · Cited by 359
“…has generally been considered a disease of DA hypofunction (for discussion see Solanto, 2002), however, a role for NA should not be excluded given that the medications currently used to treat ADHD target some component of the noradrenergic system (Biederman and Spencer, 1999; Arnsten, 2006a, b).”
BackgroundAttention-Deficit/Hyperactivity Disorder and Attention Networks
Bush, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.120 · Cited by 358
“…interested reader can find reviews of the intricacies and debates surrounding dopaminergic imaging methods (Spencer et al, 2005; Swanson et al, 2007), as well as the roles various neurotransmitters may play in the pathophysiology of ADHD (Arnsten, 2001, 2006; Brennan and Arnsten, 2008) (Figure 2).”
BackgroundRubia, K., Halari, R., Christakou, A., & Taylor, E. (2009) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2009.0014 · Cited by 310
“While the effects on the caudate were probably mediated by the dopaminergic system (Krause 2008), the effects on frontal, cingulate and cerebellar brain regions, however, could also have been influenced by noradrenaline reuptake inhibition (Arnsten 2006).”
BackgroundCingulate, Frontal, and Parietal Cortical Dysfunction in Attention-Deficit/Hyperactivity Disorder
Bush, G. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.022 · Cited by 304
Chamberlain, S. R., Hampshire, A., Müller, U., Rubia, K., del Campo, N., Craig, K., Regenthal, R., Suckling, J., Roiser, J. P., Grant, J. E., et al. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.014 · Cited by 301
Projection-Specific Neuromodulation of Medial Prefrontal Cortex Neurons
Dembrow, N. C., Chitwood, R. A., & Johnston, D. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3644-10.2010 · Cited by 285
“Neuromodulatory regulation of PFC function is a target of both the pathology and treatment of these disorders (Hyde and Crook, 2001; Bymaster and Felder, 2002; Kapur, 2003; Arnsten, 2004, 2006; Ikonomovic et al., 2007; Strawn and Geracioti, 2008; Dopheide and Pliszka, 2009; Scahill, 2009).”
BackgroundLebestky, T., Chang, J.-S. C., Dankert, H., Zelnik, L., Kim, Y.-C., Han, K.-A., Wolf, F. W., Perona, P., & Anderson, D. J. (2009) · Neuron · doi:10.1016/j.neuron.2009.09.031 · Cited by 261
“Given that DA negatively regulates environmentally stimulated arousal circuits in Drosophila, such a view would be consistent with the fact that treatment with drugs that increase synaptic levels of DA, such as methylphenidate (ritalin), can ameliorate symptoms of ADHD (Arnsten, 2006).”
Psychostimulants and Cognition: A Continuum of Behavioral and Cognitive Activation
Wood, S., Sage, J. R., Shuman, T., & Anagnostaras, S. G. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007054 · Cited by 259
Swanson, J., Baler, R. D., & Volkow, N. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.160 · Cited by 252
“This may reflect in part improved filtering out of task-irrelevant stimuli by way of stimulant-mediated DA and NE release in the PFC and anterior cingulate gyrus (Arnsten, 2006).”
BackgroundCommunication networks in the brain: neurons, receptors, neurotransmitters, and alcohol.
Lovinger, D. M. (2008) · PubMed Central · Cited by 244
Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults
Castells, X., Blanco-Silvente, L., & Cunill, R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007813.pub3 · Cited by 209
Catecholamine Dysfunction in Attention-Deficit/Hyperactivity Disorder: An Update
Prince, J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318174f92a · Cited by 205
Bush, G., Spencer, T. J., Holmes, J., Shin, L. M., Valera, E. M., Seidman, L. J., Makris, N., Surman, C., Aleardi, M., Mick, E., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.16 · Cited by 201
Attention-Deficit/Hyperactivity Disorder: A Neuropsychological Perspective Towards DSM-V
Stefanatos, G. A., & Baron, I. S. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9020-3 · Cited by 200
“, mesocortical) (Arnsten, 2006; Barkley, 1997b; Biederman & Faraone, 2005; Castellanos, 1997; Wender et al., 2001; Woods, Lovejoy, & Ball, 2002), although noradrenergic systems have also been implicated in animal studies, genetic investigations, and stimulant medication trials (Arnsten & Dudley, 2005; Biederman, 2005;…”
BackgroundTreatment of adults with attention-deficit/hyperactivity disorder
Hechtman, L. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s6985 · Cited by 157
The research domain criteria framework: The case for anterior cingulate cortex
Holroyd, C. B., & Umemoto, A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.09.021 · Cited by 187
FMRP Acts as a Key Messenger for Dopamine Modulation in the Forebrain
Wang, H., Wu, L.-J., Kim, S. S., Lee, F. J. S., Gong, B., Toyoda, H., Ren, M., Shang, Y.-Z., Xu, H., Liu, F., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.027 · Cited by 186
“However, this is consistent with the paradoxical ability of stimulants to alleviate hyperactivity in attention deficit hyperactivity disorder (ADHD), which is prevalent in fragile X patients (Arnsten, 2006; Sullivan et al., 2006).”
BackgroundPotential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Cunha, R., Ferre, S., Vaugeois, J.-M., & Chen, J.-F. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784480090 · Cited by 186
“Thus, the heritability of ADHD has been estimated to be between 0.5 and 0.9, which makes it the most heritable mental disorder among children.”
BackgroundInfluentialRubia, K., Halari, R., Cubillo, A., Smith, A. B., Mohammad, A.-M., Brammer, M., & Taylor, E. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.30 · Cited by 184
“Psychostimulants, including methylphenidate (MPH) and amphetamines, are the most effective, first-choice treatment for ADHD, improving symptoms in 70% of patients (Arnsten, 2006a; Wilens, 2008).”
InfluentialAngelidis, A., van der Does, W., Schakel, L., & Putman, P. (2016) · Biological Psychology · doi:10.1016/j.biopsycho.2016.09.008 · Cited by 179
Chamberlain, S. R., Robbins, T. W., Winder-Rhodes, S., Müller, U., Sahakian, B. J., Blackwell, A. D., & Barnett, J. H. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.019 · Cited by 178
Groman, S. M., James, A. S., & Jentsch, J. D. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.08.008 · Cited by 177
“…show an increase in norepinephrine release in the prefrontal cortex that depends upon autoreceptor sub-sensitivity (Russell et al. 2000; Russell and Wiggins 2000); alterations in prefrontal cortical noradrenergic tone have been implicated in the cognitive control deficits in ADHD (Arnsten 2006a).”
BackgroundPrefrontal cortex executive processes affected by stress in health and disease
Girotti, M., Adler, S. M., Bulin, S. E., Fucich, E. A., Paredes, D., & Morilak, D. A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.07.004 · Cited by 176
“Morilak , Prefrontal cortex executive processes affected by stress in health and disease. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Pnp(2017), doi: 10.”
BackgroundRubia, K., Halari, R., Mohammad, A.-M., Taylor, E., & Brammer, M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.018 · Cited by 171
Inagaki, T., Gautreaux, C., & Luine, V. (2010) · Hormones and Behavior · doi:10.1016/j.yhbeh.2010.05.013 · Cited by 163
“Several lines of evidence indicate that the PFC is extremely sensitive to changes in the neuromodulatory inputs from NE and DA systems (Arnsten, 2006, 2007; Arnsten and Robbins, 2002; Robbins and Arnsten, 2009).”
Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses
Genro, J. P., Kieling, C., Rohde, L. A., & Hutz, M. H. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.17 · Cited by 130
Cognitive enhancement as a pharmacotherapy target for stimulant addiction
Sofuoglu, M. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02791.x · Cited by 161
Berridge, C. W., & Devilbiss, D. M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.023 · Cited by 160
Pei, Y., Asif-Malik, A., & Canales, J. J. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00148 · Cited by 159
Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women
Smid, M. C., Metz, T. D., & Gordon, A. J. (2019) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000418 · Cited by 157
Fried, M., Tsitsiashvili, E., Bonneh, Y. S., Sterkin, A., Wygnanski-Jaffe, T., Epstein, T., & Polat, U. (2014) · Vision Research · doi:10.1016/j.visres.2014.05.004 · Cited by 154
“Since there is a long washout period for MPH, we used a fixed order medicationlast design, and in order to control for possible carry-over effects attributed to either learning or fatigue, the control subjects also ran the session twice, with the same time gap between sessions.”
BackgroundInfluentialSpencer, T. J., Brown, A., Seidman, L. J., Valera, E. M., Makris, N., Lomedico, A., Faraone, S. V., & Biederman, J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08287 · Cited by 139
Circadian insights into dopamine mechanisms
Mendoza, J., & Challet, É. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.07.081 · Cited by 139
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
“They were both authorised by the FDA in 2010, respectively alone and for adjunctive use with stimulants, in comparison to which they are less efficacious, most likely since they lack the D1 receptor component of activity recruited by stimulants (Arnsten, 2006; Bidwell et al, 2010; Connor et al., 2014; Felt et al., 201…”
MethodPharmacological Enhancement of Memory and Executive Functioning in Laboratory Animals
Floresco, S., & Jentsch, J. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.158 · Cited by 129
Devilbiss, D. M., & Berridge, C. W. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.037 · Cited by 128
“gain of neuronal activity), consistent with known actions of catecholamines on cortical neurons (4,6,18,34,38,45,46).”
BackgroundThe Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder
Viktorin, A., Rydén, E., Thase, M. E., Chang, Z., Lundholm, C., D’Onofrio, B. M., Almqvist, C., Magnusson, P. K. E., Lichtenstein, P., Larsson, H., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16040467 · Cited by 112
Zhu, J., Zhang, X., Xu, Y., Spencer, T. J., Biederman, J., & Bhide, P. G. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1041-12.2012 · Cited by 125
“We focused on frontal cortical dopamine because cortical hypodopaminergic state is considered a hallmark of ADHD and it is a therapeutic target of MPH (Kuczenski and Segal, 2001, 2005; Robbins, 2002; Seeman and Madras, 2002; Volkow et al., 2005; Arnsten, 2006).”
BackgroundAmphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Punja, S., Shamseer, L., Hartling, L., Urichuk, L., Vandermeer, B., Nikles, J., & Vohra, S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009996.pub2 · Cited by 122
“In either case, as a psychostimulant, amphetamines are thought to disrupt normal reuptake of neurotransmitters thereby increasing levels of norepinephrine and dopamine in these regions of the brain and resulting in restored executive functioning (Arnsten 2006).”
BackgroundInfluentialBari, A., Xu, S., Pignatelli, M., Takeuchi, D., Feng, J., Li, Y., & Tonegawa, S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015635117 · Cited by 121
Angelidis, A., Hagenaars, M. A., Son, D. V., van der Does, W. A. J., & Putman, P. (2018) · Biological Psychology · doi:10.1016/j.biopsycho.2018.03.002 · Cited by 117
Neural Substrates of Psychostimulant Withdrawal-Induced Anhedonia
D’Souza, M. S., & Markou, A. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_20 · Cited by 116
“Patients with attention deficit hyperactivity disorder (ADHD) are treated with psychostimulant compounds, such as methylphenidate, to calm agitated/hyperactive behavior (Arnsten 2006).”
BackgroundAngelidis, A., Solis, E. C., Lautenbach, F., van der Does, W. A. J., & Putman, P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210824 · Cited by 115
Son, D. V., de Rover, M., Blasio, F. M. D., van der Does, W. A. J., Barry, R. J., & Putman, P. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14180 · Cited by 113
Schweren, L., de Zeeuw, P., & Durston, S. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.10.014 · Cited by 110
Franke, A. G., Gränsmark, P., Agricola, A., Schühle, K., Rommel, T., Sebastian, A., Balló, H. E., Gorbulev, S., Gerdes, C., Frank, B., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.01.006 · Cited by 110
The effects of methylphenidate on whole brain intrinsic functional connectivity
Mueller, S., Costa, A. C. L., Keeser, D., Pogarell, O. M., Berman, A., Coates, U., Reiser, M. F., Riedel, M. J., Möller, H., Ettinger, U., et al. (2014) · Human Brain Mapping · doi:10.1002/hbm.22557 · Cited by 109
“Given that MPH induces wide-spread activity changes during spatial working memory [Marquand et al., 2011] and based on the described MPH effects and side effects in ADHD [Rubia et al., 2009b; Stiefel and Besag, 2010; Yildiz et al., 2011] and other neuro-psychiatric diseases [Auriel et al., 2009; Ng, 2008; Padala et al…”
BackgroundInfluentialZisner, A., & Beauchaine, T. P. (2016) · Development and Psychopathology · doi:10.1017/s0954579416000754 · Cited by 92
“DA agonists may also reduce novelty- and sensation-seeking behaviors by diminishing an organism’s dependence on immediately available rewarding stimuli to increase striatal activation (Arnsten, 2006).”
BackgroundMethylphenidate Disrupts Social Play Behavior in Adolescent Rats
Vanderschuren, L. J. M. J., Trezza, V., Griffioen-Roose, S., Schiepers, O. J. G., Van Leeuwen, N., De Vries, T. J., & Schoffelmeer, A. N. M. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.10 · Cited by 105
Sadasivan, S., Pond, B. B., Pani, A. K., Qu, C., Jiao, Y., & Smeyne, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033693 · Cited by 102
“Methylphenidate (MPH; marketed under trade names ConcertaH MetadateH, MethylinH, RitalinH) is one of the most commonly prescribed stimulant medications for the symptomatic management of ADHD and narcolepsy [1,2,3].”
BackgroundNeuroimaging and ADHD: fMRI, PET, DTI Findings, and Methodological Limitations
Weyandt, L. L., Swentosky, A. J., & Guðmundsdóttir, B. G. (2013) · Developmental Neuropsychology · doi:10.1080/87565641.2013.783833 · Cited by 102
Connor, D. F., Findling, R. L., Kollins, S. H., Sallee, F., López, F. A., Lyne, A., & Tremblay, G. (2010) · CNS Drugs · doi:10.2165/11537790-000000000-00000 · Cited by 101
Marquand, A. F., De Simoni, S., O'Daly, O. G., Williams, S. C., Mourão-Miranda, J., & Mehta, M. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.9 · Cited by 95
“Catecholaminergic signalling has also been associated with an ‘inverted-U’ dose-response relationship in the PFC (Arnsten, 2006; Levy, 2009) with optimal PFC function at intermediate concentrations and too much or too little DA or NA resulting in impaired PFC function.”
BackgroundInfluentialHeath, C. J., & Picciotto, M. R. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.020 · Cited by 99
“The data showing that developmental nicotine exposure results in alterations in DA and NE in the neocortex is significant, since catecholaminergic signaling in the prefrontal cortex is thought to be disrupted in patients (Arnsten, 2006b).”
Spontaneously hypertensive rat (SHR) as an animal model for ADHD: a short overview
Meneses, A., Perez-Garcia, G., Ponce-Lopez, T., Tellez, R., Gallegos-Cari, A., & Castillo, C. (2011) · revneuro · doi:10.1515/rns.2011.024 · Cited by 84
Vaidya, C. J., & Stollstorff, M. (2008) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.40 · Cited by 95
Structural and functional brain imaging in adult attention-deficit/hyperactivity disorder
Cubillo, A., & Rubia, K. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.4 · Cited by 80
Monden, Y., Dan, H., Nagashima, M., Dan, I., Tsuzuki, D., Kyutoku, Y., Gunji, Y., Yamagata, T., Watanabe, E., & Momoi, M. Y. (2012) · NeuroImage: Clinical · doi:10.1016/j.nicl.2012.10.001 · Cited by 89
“MPH is considered to inhibit reuptake of catecholamines, including dopamine, by blocking their transporters and to act as a dopamine agonist in the basal ganglia and cerebral cortices (Arnsten, 2006).”
BackgroundZhou, R., Bai, Y., Yang, R., Zhu, Y., Chi, X., Li, L., Chen, L., Sokabe, M., & Chen, L. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.031 · Cited by 92
“Evidence obtained from animal models of ADHD suggests that dopaminergic systems are functionally impaired, thus the dopaminergic neurotransmitter may be the target of drugs that ameliorate ADHD symptoms.”
InfluentialXu, T.-X., Sotnikova, T. D., Liang, C., Zhang, J., Jung, J. U., Spealman, R. D., Gainetdinov, R. R., & Yao, W.-D. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0974-09.2009 · Cited by 76
“In addition, although the beneficial effects of stimulants in improving attention and cognition have been well recognized, it is now clear that high doses of amphetamine impair prefrontal cognitive functions (Arnsten, 2006; Ko and Evenden, 2009; Wood and Anagnostaras, 2009).”
BackgroundCognitive enhancers in the treatment of substance use disorders: Clinical evidence
Brady, K. T., Gray, K. M., & Tolliver, B. K. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.017 · Cited by 82
“Guanfacine, a selective agonist of the α-2A adrenergic receptor found in high density in the PFC, is another noradrenergic medication approved for treatment of ADHD in children (Ramos and Arnsten, 2007).”
BackgroundDopamine vs Noradrenaline: Inverted-U Effects and ADHD Theories
Levy, F. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670802607238 · Cited by 78
“noise) and thus enhance spatial tuning [17].”
BackgroundRobinson, E. S. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2420-3 · Cited by 87
“The majority of patients are treated with non-specific catecholaminergic and stimulant medications such as methylphenidate and amphetamine although more recently, selective noradrenergic compounds have shown efficacy and benefit from reduced side effects (Arnsten 2006; Wilens 2006; Arnsten et al. 2007).”
BackgroundExecutive Impairment Determines ADHD Medication Response: Implications for Academic Achievement
Hale, J. B., Reddy, L. A., Semrud-Clikeman, M., Hain, L. A., Whitaker, J., Morley, J., Lawrence, K., Smith, A., & Jones, N. (2011) · Journal of Learning Disabilities · doi:10.1177/0022219410391191 · Cited by 74
“Although MPH clearly enhances executive modulation of cognition and behavior, evidence is emerging that differences among dopamine receptors (Floresco & Magyar, 2006) could lead to differential MPH effects, with low doses improving attention control and working memory and higher doses impairing these functions (Arnste…”
BackgroundResultHung, C.-L., Huang, C.-J., Tsai, Y.-J., Chang, Y.-K., & Hung, T.-M. (2016) · Frontiers in Psychology · doi:10.3389/fpsyg.2016.01589 · Cited by 72
“This dopamine hypothesis is also consistent with stimulant treatment, such as with MPH, which increases dopamine levels by blocking dopamine transporters (Swanson and Volkow, 2003) and improves performance on aspects of executive function including spatial working memory, response inhibition, and setshifting (Arnsten,…”
ResultWinstanley, C. A., Zeeb, F. D., Bedard, A., Fu, K., Lai, B., Steele, C., & Wong, A. C. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.02.044 · Cited by 84
“One explanation for suchfindings is that the relationship betweenDAactivation and performance follows an “inverted U-shaped curve”, with both too much and too little DA having similar behavioural consequences [31,53].”
BackgroundSubstance Use in Adolescence and Psychosis: Clarifying the Relationship
Barkus, E., & Murray, R. M. (2010) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.121208.131220 · Cited by 68
Peña, I. D., Pan, M. C., Thai, C. G., & Alisso, T. (2020) · Brain Sciences · doi:10.3390/brainsci10050292 · Cited by 82
Bolaños, C. A., Wiley, M. D., Maffeo, M. L., Powers, K. D., Kinka, D. W., Grausam, K. B., & Henderson, R. P. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.024 · Cited by 81
Monden, Y., Dan, H., Nagashima, M., Dan, I., Kyutoku, Y., Okamoto, M., Yamagata, T., Momoi, M. Y., & Watanabe, E. (2011) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.10.006 · Cited by 81
“MPH is believed to inhibit the reuptake of catecholamines, including dopamine, by blocking their transporters, and it acts as a dopamine agonist in the basal ganglia and cerebral cortices (Arnsten, 2006).”
BackgroundJanssen, T. W. P., Bink, M., Geladé, K., van Mourik, R., Maras, A., & Oosterlaan, J. (2016) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12517 · Cited by 63
“pinephrine fronto-striatal circuitry (Arnsten, 2006).”
Wong, C. G., & Stevens, M. C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.11.011 · Cited by 80
Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults
Castells, X., Ramos-Quiroga, J. A., Bosch, R., Nogueira, M., & Casas, M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007813.pub2 · Cited by 80
Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats
Nikiforuk, A., Gołembiowska, K., & Popik, P. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.08.001 · Cited by 77
Mergy, M. A., Gowrishankar, R., Gresch, P. J., Gantz, S. C., Williams, J. T., Davis, G. L., Wheeler, C. A., Stanwood, G. D., Hahn, M. K., & Blakely, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417294111 · Cited by 76
The Neurobiology of Reading and Dyslexia
Shaywitz, S. E., & Shaywitz, B. A. (2007) · ASHA Leader · doi:10.1044/leader.ftr7.12122007.20 · Cited by 75
Madhoo, M., Keefe, R. S., Roth, R. M., Sambunaris, A., Wu, J., Trivedi, M. H., Anderson, C. S., & Lasser, R. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.334 · Cited by 74
“Stimulants, such as those used to treat attention-deficit/hyperactivity disorder (ADHD), preferentially modulate central DA and, to a lesser extent, NE systems (Arnsten, 2006).”
BackgroundMowinckel, A. M., Alnæs, D., Pedersen, M. L., Ziegler, S., Fredriksen, M., Kaufmann, T., Sonuga-Barke, E., Endestad, T., Westlye, L. T., & Biele, G. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.03.008 · Cited by 60
“…in dopamine (DA) dense fronto-striatal and mesolimbic brain networks in ADHD due to the inhibition of synaptic reuptake of DA in these networks (Arnsten, 2006; Volkow et al., 2009, 2005) – effects that are reflected in improved functioning in executive functions and reward processing in ADHD…”
Fumagalli, F., Cattaneo, A., Caffino, L., Ibba, M., Racagni, G., Carboni, E., Gennarelli, M., & Riva, M. A. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.07.009 · Cited by 73
Cognitive Activation by Central Thalamic Stimulation: The Yerkes-Dodson Law Revisited
Mair, R. G., Onos, K. D., & Hembrook‐Short, J. R. (2010) · Dose-Response · doi:10.2203/dose-response.10-017.mair · Cited by 73
Methylphenidate Effects on Neural Activity During Response Inhibition in Healthy Humans
Costa, A. C. L., Riedel, M. J., Pogarell, O. M., Menzel-Zelnitschek, F., Schwarz, M., Reiser, M. F., Möller, H., Rubia, K., Meindl, T., & Ettinger, U. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhs107 · Cited by 73
From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate
Busardò, F. P., Kyriakou, C., Cipolloni, L., Zaami, S., & Frati, P. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150407225902 · Cited by 73
“It has been shown that working memory performance is facilitated after a low dose of MPD infusion in PFC, whereas infusion of MPD into striatum has no reaction on this PFC-dependent cognition task [37], suggesting that PFC is a main site for MPD’s therapeutic action [38, 39].”
BackgroundPositron emission tomography neuroimaging for a better understanding of the biology of ADHD
Zimmer, L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.001 · Cited by 72
Dual dopamine/serotonin releasers: Potential treatment agents for stimulant addiction.
Rothman, R. B., Blough, B. E., & Baumann, M. H. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0014103 · Cited by 71
“In some cases, as with amphetamine, the same drug can be a therapeutic entity or an abused substance, depending upon the context in which the drug is administered (Arnsten, 2006; Greenhill, 2006).”
BackgroundLocus coeruleus neurons encode the subjective difficulty of triggering and executing actions
Bornert, P., & Bouret, S. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001487 · Cited by 70
The Cambridge Handbook of Substance and Behavioral Addictions
Sussman, S. Y. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591 · Cited by 69
Silvagni, A., Barros, V. G., Mura, C., Antonelli, M. C., & Carboni, E. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06364.x · Cited by 58
Ni, H.-C., Shang, C.-Y., Gau, S. S.-F., Lin, Y.-J., Huang, H.-C., & Yang, L.-K. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000357 · Cited by 61
“Dysregulated dopaminergic and noradrenergic neurotransmission has been widely implicated in the pathophysiology of ADHD (Arnsten, 2006a).”
Challenge-driven attention: Interacting frontal and brainstem systems
Raizada, R. D. S. (2008) · Frontiers in Human Neuroscience · doi:10.3389/neuro.09.003.2007 · Cited by 61
“, 1999), and which has been found to be amenable to treatment by noradrenergic drugs (Arnsten, 2006; Scahill et al., 2001; Solanto, 1998).”
BackgroundArousal and Executive Alterations in Attention Deficit Hyperactivity Disorder (ADHD)
Martella, D., Aldunate, N., Fuentes, L. J., & Sánchez‐Pérez, N. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.01991 · Cited by 69
“Furthermore, the atomoxetine, a drug e ectively used for ADHD treatment, acts as an inhibitor highly selective of noradrenergic reuptake (Arnsten, 2006), which strongly supports a relationship between NE and ADHD.”
BackgroundHollis, C., Chen, Q., Chang, Z., Quinn, P. D., Viktorin, A., Lichtenstein, P., D'Onofrio, B., Landén, M., & Larsson, H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30189-0 · Cited by 65
Tuura, R., Mehta, M. A., Asherson, P. J., Zelaya, F. O., Brookes, K. J., Toone, B., Alsop, D. C., & Williams, S. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.04.169 · Cited by 65
“Currently ADHD is predominantly treated with stimulant medications such as methylphenidate or amphetamine, which primarily release and prevent the reuptake of catecholamines (dopamine and noradrenaline), increasing the activity of these neurotransmitter systems (Seeman and Madras, 1998; Arnsten, 2006).”
BackgroundPardey, M. C., Kumar, N. N., Goodchild, A. K., & Cornish, J. L. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112465497 · Cited by 61
“The inverted U relationship between DA, NE and PFC function indicates that extreme levels of DA and NE are detrimental to PFC functioning, whilst optimal PFC function requires moderate levels of DA and NE neurotransmission (Arnsten, 2006, 2009).”
Background
Metadata
- Authors
- Arnsten, A. F. T.
- Affiliations
- Yale University (US)
- Corresponding author
- Arnsten, Amy F T
- ORCID
- Arnsten, Amy F T
- Venue
- Neuropsychopharmacology
- Published
- 2006-07-19
- Volume
- 31
- Issue
- 11
- Pages
- 2376-2383
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1989057449
- Cited by
- 473
- References
- 110
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 18 · 2023: 14 · 2022: 19 · 2021: 20 · 2020: 59 · 2019: 11 · 2018: 20 · 2017: 13 · 2016: 30 · 2015: 16 · 2014: 23 · 2013: 27 · 2012: 36
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Yale University
- Shire
- National Institutes of Health (5r21mh066393-03)
- National Institute on Aging (R37AG006036, R37 AG06036)
- National Institute of Mental Health (R21-MH066393)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Keywords
- attention deficit hyperactivity disorder, stimulant medication, methylphenidate, amphetamine, prefrontal cortex, norepinephrine, dopamine, catecholamines, alpha2-adrenoceptors, dopamine D1 receptor, alpha1-adrenoceptors, working memory, executive function, attention, locomotor activity
- MeSH terms
- Central Nervous System Stimulants, Animals, Attention Deficit Disorder with Hyperactivity, Catecholamines, Dose-Response Relationship, Drug, Humans, Methylphenidate, Prefrontal Cortex
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.